Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature

Med Oncol. 2010 Mar;27(1):55-8. doi: 10.1007/s12032-009-9170-7. Epub 2009 Feb 11.

Abstract

Appearance of non-Hodgkin's lymphomas (NHL) and renal cell carcinoma (RCC) in same person has been reported in the literature. There is a higher-than-expected incidence of co-occurrence of these neoplastic disorders. The cause for this association remains speculative. Two epidemiological studies have shown that the observed-to-expected ratio for occurrence of RCC in NHL patients were 1.86 to 2.67. We herein describe five patients with both RCC and lymphoid malignancies, and reviewed possible explanations for the association. In three of the five patients, RCC was diagnosed during lymphoproliferative disease work-up, and remaining two cases had been diagnosed with chronic lymphocytic leukemia 1 and 5 years prior to RCC. All RCC cases were detected during staging of the primary tumor, usually by CT scan and/or ultrasound. Our data are in correlation with the literature that there is an increased association of RCC and NHL more often among male patients, and that the lymphoproliferative disease often presents with extranodal involvement. The specialists should be alerted for this possibility when evaluating patients at diagnosis or during follow-up.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Renal Cell / complications*
  • Carcinoma, Renal Cell / diagnosis
  • Carcinoma, Renal Cell / surgery
  • Hepatomegaly / diagnostic imaging
  • Hepatomegaly / etiology
  • Humans
  • Kidney Neoplasms / complications*
  • Kidney Neoplasms / diagnosis
  • Kidney Neoplasms / surgery
  • Leukemia, B-Cell / complications*
  • Leukemia, B-Cell / diagnosis
  • Leukemia, B-Cell / drug therapy
  • Male
  • Nephrectomy
  • Remission Induction
  • Sex Factors
  • Splenomegaly / diagnostic imaging
  • Splenomegaly / etiology
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents